Promising Results from Prostate Device Study

Published date : 03 October 2012
Article date : 03 October 2012 reports on a study about a device designed for use in the treatment of prostate cancer which states that it can discriminate between cancer and healthy tissue with “a very high degree of accuracy.” 

Apparently, the MarginProbe System is Dune Medical Devices's first commercial product and it is now approved and available in Europe for use in detecting diseased tissue in breast cancer patients. A prototype of the device for prostate cancer is based on the same technology but shaped differently than the breast cancer device. It is now in feasibility studies.

The study published in involved more than 15,000 measurements in 49 patients. The abstract from the study reported the device's ability to discriminate between malignant and nonmalignant cells with a sensitivity and specificity of between 68.4% and 93.6% depending on the size of the cancer. The abstract of the article concludes, "First results from a radio-frequency near-field spectroscopy sensor look promising for differentiation between cancer and benign prostate tissue."

Source: By Don Seiffert,, 17 September 2012

Read the original article here

Back to Listings

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.